Ylva Almqvist

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. ncbi request reprint In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer
    Ylva Almqvist
    Division of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Nucl Med Biol 33:991-8. 2006
  2. ncbi request reprint In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma
    Ylva Almqvist
    Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 20:514-23. 2005
  3. ncbi request reprint Biodistribution of 211At-labeled humanized monoclonal antibody A33
    Ylva Almqvist
    Unit of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Sweden, and Department of Clinical Physiology and Nuclear Medicine, PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark
    Cancer Biother Radiopharm 22:480-7. 2007
  4. ncbi request reprint Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:1348-56. 2003
  5. ncbi request reprint Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
    Ann Charlott Steffen
    Unit of Biomedical Radiation Sciences, Department of Oncology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Oncol Rep 17:1141-7. 2007
  6. ncbi request reprint Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition
    Asa Liljegren Sundberg
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:727-9. 2003
  7. ncbi request reprint [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation
    Mohammad Hossein Babaei
    Radioisotope Division, Nuclear Research Center, Atomic Energy Organisation of Iran, Tehran, Iran
    Oncol Rep 13:1169-75. 2005

Collaborators

Detail Information

Publications7

  1. ncbi request reprint In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer
    Ylva Almqvist
    Division of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Nucl Med Biol 33:991-8. 2006
    ..The aim of this study was to determine the biodistribution and tumor-targeting ability of (177)Lu-labeled huA33...
  2. ncbi request reprint In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma
    Ylva Almqvist
    Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 20:514-23. 2005
    ..The (211)At-A33 conjugate shows promise as a potential radioimmunotherapy agent for treatment of micrometastases originating from colorectal carcinoma...
  3. ncbi request reprint Biodistribution of 211At-labeled humanized monoclonal antibody A33
    Ylva Almqvist
    Unit of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Sweden, and Department of Clinical Physiology and Nuclear Medicine, PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark
    Cancer Biother Radiopharm 22:480-7. 2007
    ..In conclusion, the favorable biodistribution and specific in vivo targeting ability of 211At-huA33 makes it a potential therapeutic agent for the RIT of metastatic colorectal carcinoma...
  4. ncbi request reprint Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:1348-56. 2003
    ..These results indicate that combined treatment with gefitinib might increase the effect of ligand-mediated radionuclide therapy in gefitinib-resistant tumours and decrease the effect of such therapy in gefitinib-sensitive tumours...
  5. ncbi request reprint Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
    Ann Charlott Steffen
    Unit of Biomedical Radiation Sciences, Department of Oncology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Oncol Rep 17:1141-7. 2007
    ..However, the labeling chemistry affects the distribution in normal organs to a high degree and needs to be improved to allow clinical use...
  6. ncbi request reprint Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition
    Asa Liljegren Sundberg
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:727-9. 2003
    ..This indicates that a combination of gefitinib treatment and radionuclide targeting to EGFR might be a useful therapeutic modality, even for patients who do not respond to treatment with gefitinib alone...
  7. ncbi request reprint [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation
    Mohammad Hossein Babaei
    Radioisotope Division, Nuclear Research Center, Atomic Energy Organisation of Iran, Tehran, Iran
    Oncol Rep 13:1169-75. 2005
    ..Biodistribution of (99m)Tc-EDDA-HYNIC-EGF in normal mice demonstrated fast blood clearance of conjugate, and its ability to bind EGFR in vivo. (99m)Tc-EDDA-HYNIC-EGF is a promising candidate for visualization of EGFR expression in vivo...